GSK is acquiring lung cancer biotech Nuvalent in its biggest deal in over a decade
Quartz
—
The all-cash deal, GSK's largest in more than a decade, gives the British drugmaker two late-stage lung cancer drugs under FDA review
GSK Acquires Nuvalent for $10.6 Billion
- GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down MarketWatch —
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn The Guardian —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Argus —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Standard —
- GSK agrees to buy US cancer drug firm Nuvalent in £8bn deal Yorkshire Post —